The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 7 February 2012 up to and including 13 February 2013 the Company bought 13439 own shares representing 0.0102% of the share capital of the Company, to the total value of BGN 30490.38 on the Bulgarian Stock Exchange. The average price per share was BGN 2.27.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3573808, representing 2.71% of the share capital of the Company.
The Board of Directors of Sopharma AD (the “Company”) announces that the Company sold 1105000 ordinary registered shares with voting rights, representing 3.36% of the share of the capital of Sopharma Trading AD. After this transaction the share of Sopharma AD in the capital of Sopharma Trading AD decreased below 80% to 76.77%.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 14 February 2012 up to and including 20 February 2013 the Company bought 9400 own shares representing 0.0071% of the share capital of the Company, to the total value of BGN 20757.75 on the Bulgarian Stock Exchange. The average price per share was BGN 2.21.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3583208, representing 2.71% of the share capital of the Company.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 21 February 2013 up to and including 27 February 2013 the Company bought 29950 own shares representing 0.023% of the share capital of the Company, to the total value of BGN 64015.26 on the Bulgarian Stock Exchange. The average price per share was BGN 2.14.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3613158, representing 2.74% of the share capital of the Company.
The Board of Directors of Sopharma AD (the “Company”) notifies that for February 2013 Sopharma AD realized an increase of sales revenues of 6% compared to the same period of 2012, including 2% decrease of domestic sales and 8% increase of export sales.
During the past two months Sopharma AD recorded a decrease of sales revenues of 2%, including 2% decrease of export sales and same level of domestic sales compared to 2012.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 28 February 2013 up to and including 6 March 2013 the Company bought 7941 own shares representing 0.006% of the share capital of the Company, to the total value of BGN 17463.89 on the Bulgarian Stock Exchange. The average price per share was BGN 2.20.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3621099, representing 2.74% of the share capital of the Company.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 7 March 2013 up to and including 13 March 2013 the Company bought 16080 own shares representing 0.012% of the share capital of the Company, to the total value of BGN 36047.53 on the Bulgarian Stock Exchange. The average price per share was BGN 2.24.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3637179, representing 2.755% of the share capital of the Company.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 14 March 2013 up to and including 20 March 2013 the Company bought 15688 own shares representing 0.012% of the share capital of the Company, to the total value of BGN 3578,38 on the Bulgarian Stock Exchange. The average price per share was BGN 2.28.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3652867, representing 2.767% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 19 December 2013 up to and including 8 January 2014 the Company bought 34 045 own shares representing 0.026% of the share capital of the Company, to the total value of 133 491.80 BGN on the Bulgarian Stock Exchange. The average price per share was 3.92 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 488 911, representing 4.16% of the share capital of the Company.
Sopharma AD (the “Company”) notifies that for December 2013 the Company recorded an increase of sales revenues of 63% compared to the same period of 2012, including 31% increase of domestic sales and 102% increase of export sales.
During the past year Sopharma AD recorded an increase of sales revenues of 3%, including 7% increase of domestic sales and 1% increase of export sales compared to 2012.